Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002551 | 0.88 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL10965456 | 0.85 | LOXL2 (0.59) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| Hydrochloric Acid SCHEMBL6364657 | 0.83 | LOXL2 (0.57) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL2652782 | 0.83 | CYP4A11 (0.61) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL70185 | 0.83 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL5085645 | 0.83 | CYP4A11 (0.45) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL8337316 | 0.83 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL5088454 | 0.82 | ALDH1A1 (0.44) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL3633353 | 0.81 | CYP4A11 (0.58) | CYP4A11CYP4F2LOXL2CA1CA2 | |
| SCHEMBL8487728 | 0.81 | CYP4A11 (0.54) | CYP4A11CYP4F2LOXL2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023309-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109923109-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | US | disclosed |
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-15 | — | — | US | disclosed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3510028-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-18 | — | — | US | disclosed |
| EP-3510028-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3510026-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| CN-110023309-A | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109923109-A | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| WO-2018048763-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018048762-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | CYP4A11 448/4885CYP4F2 961/4885LOXL2 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.